NCT03723395View on ClinicalTrials.gov

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

PHASE1CompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 17, 2018

Primary Completion Date

December 21, 2018

Study Completion Date

December 28, 2018

Conditions
Drug-drug Interaction
Interventions
DRUG

tucatinib

300mg dose, orally administered

DRUG

itraconazole

200mg dose

DRUG

rifampin

600mg dose

DRUG

gemfibrozil

600mg tablets

DRUG

repaglinide

1mg dose

DRUG

tolbutamide

500mg dose

DRUG

midazolam

2mg dose

DRUG

digoxin

0.5 mg dose

Trial Locations (2)

32117

Covance Clinical Research Unit, Daytona Beach

75247

Covance Clinical Research Unit, Dallas

All Listed Sponsors
lead

Seagen Inc.

INDUSTRY

NCT03723395 - A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib | Biotech Hunter | Biotech Hunter